The current paper reports a survey on intrahepatic cholestasis of pregnancy (ICP), concerning obstetric outcomes and treatment of the disease. The survey assessed the opinions of contributors on ursodeoxycholic acid (UDCA) therapy and ICP care. It was administered online on behalf of the editorial office of Clinical & Experimental Obstetrics and Gynecology. Ten questions were provided to the scholars, fellows and peers. Nine questions of the survey allowed closed answers, while the tenth question was open. Semantic Brand Score (https://semanticbrandscore.com/) was used to conduct the survey and to extract the key concepts on ICP. Despite the unclear roles of ursodeoxycholic acid in ICP, respondents believed that reducing the bile acid using ursodeoxycholic acid was beneficial to prevent adverse pregnancy outcomes. The three key-concepts frequently reported by respondents in the optional text responses were (1) disease severity, (2) need for research, and (3) management. In conclusion, respondents demonstrated a marked disparity in their understanding and use of ursodeoxycholic acid in ICP, highlighting the importance of urgent update of international guidelines, in the light of recent publications.